# J.C. Lee

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/j-c-lee/

## Facts

| Field | Value |
| --- | --- |
| Citations | 15 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 2 |
| i10-index | 0 |
| Last Known Institution | Asan Medical Center |
| OpenAlex ID | https://openalex.org/A5006211765 |
| Works | 24 |

## Researcher papers

- [Morphological characteristics of the upper airway and pressure drop analysis using 3D CFD in OSA patients](https://scholariq.org/papers/morphological-characteristics-of-the-upper-airway-and-pressure-drop-analysis/)
- [132 Epithelial to Mesenchymal Transition Leads to Crizotinib-resistance in H2228 Lung Cancer Cells with EML4-ALK Translocation](https://scholariq.org/papers/132-epithelial-to-mesenchymal-transition-leads-to-crizotinib-resistance-in-h2228/)
- [P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession](https://scholariq.org/papers/p2-01-46-the-efficacy-and-safety-of-2nd-line-nivolumab-for-non-small-cell-lung/)
- [Randomized Phase Ii Study of Belotecan or Topotecan Chemotherapy As Second-Line Chemotherapy After Platinum-Based First-Line Chemotherapy for Small Cell Lung Cancer](https://scholariq.org/papers/randomized-phase-ii-study-of-belotecan-or-topotecan-chemotherapy-as-second-line/)
- [P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation](https://scholariq.org/papers/p2-13-22-resistant-patterns-to-osimertinib-in-non-small-cell-lung-cancer/)
- [413P South Korean real-world treatment patterns in patients with EGFRm NSCLC](https://scholariq.org/papers/413p-south-korean-real-world-treatment-patterns-in-patients-with-egfrm-nsclc/)
- [1167P Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis](https://scholariq.org/papers/1167p-central-nervous-systemic-efficacy-of-immune-checkpoint-inhibitors-and/)
- [P1.28-12 Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy](https://scholariq.org/papers/p1-28-12-korean-real-world-data-on-unresectable-stage-iii-non-small-cell-lung/)
- [P3.08F.06 PLATINUM Trial: Preliminary Analysis of Lazertinib Therapy in Locally Advanced, Unresectable, EGFR Mutation(+) NSCLC Following CCRT](https://scholariq.org/papers/p3-08f-06-platinum-trial-preliminary-analysis-of-lazertinib-therapy-in-locally/)
- [Re-biopsy for advanced non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy: CT characteristics of patients with T790M mutation and the use of various re-biopsy procedures](https://scholariq.org/papers/re-biopsy-for-advanced-non-small-cell-lung-cancer-after-egfr-tyrosine-kinase/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Asan Medical Center](https://scholariq.org/institutions/asan-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.